Not logged in.png)
Share.png)
SaveSocioeconomic and financial factors associated with financial toxicity in Japanese cancer patients: a cross-sectional study
Yokoyama, Kazuki; Honda, Kazunori; Matsumoto, Kazuko; Ando, Yayoi; Ito, Munehiro; Goto, Rei; Shinno, Yuki; Shimoi, Tatsunori; Suzuki, Tatsuya; Yoshioka, Takashi; Ishiki, Hiroto Share Save Share Save Share Save Share Save Midline catheter use for cancer patients receiving 5-FU chemotherapy: prospective study of safety and outcomesSakakida, Tomoki; Fukahori, Shinichiro; Mizuno, Taro; Ishizuka, Yasunobu; Wakabayashi, Munehiro; Kodama, Hiroyuki; Narita, Yukiya; Masuishi, Toshiki; Honda, Kazunori; Kadowaki, Shigenori; Ando, Masashi; Muro, Kei; Ogawa, Akinobu; Kudo, Chiho; Oze, Isao Share Save Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5-Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort StudyKumanishi, Ryosuke; Taniguchi, Hiroya; Nakazawa, Taiko; Ogata, Takatsugu; Matsubara, Yuki; Kodama, Hiroyuki; Nakata, Akinobu; Honda, Kazunori; Masuishi, Toshiki; Narita, Yukiya; Kadowaki, Shigenori; Ando, Masashi; Tajika, Masahiro; Abe, Tetsuya; Muro, Kei Share Save Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational studyNarita, Yukiya; Mizuno, Taro; Ishizuka, Yasunobu; Sakakida, Tomoki; Masuishi, Toshiki; Taniguchi, Hiroya; Kadowaki, Shigenori; Honda, Kazunori; Ando, Masashi; Tajika, Masahiro; Takahari, Daisuke; Muro, Kei Share Save Impacts of time-of-day of nivolumab infusion on treatment efficacy for patients with head and neck squamous cell carcinomaTsunoki, T.; Kadowaki, S.; Mizuno, T.; Ishizuka, Y.; Sakakida, T.; Narita, Y.; Honda, K.; Masuishi, T.; Taniguchi, H.; Ando, M.; Muro, K.; Hanai, N. Share Save Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational studyNarita, Yukiya; Ogata, Takatsugu; Ishizuka, Yasunobu; Sakakida, Tomoki; Wakabayashi, Munehiro; Kodama, Hiroyuki; Honda, Kazunori; Masuishi, Toshiki; Taniguchi, Hiroya; Kadowaki, Shigenori; Ando, Masashi; Tajika, Masahiro; Muro, Kei Share Save Chronological improvement of survival in patients with advanced gastric cancer over 15 yearsOgata, Takatsugu; Narita, Yukiya; Oze, Isao; Kumanishi, Ryosuke; Nakazawa, Taiko; Matsubara, Yuki; Kodama, Hiroyuki; Nakata, Akinobu; Honda, Kazunori; Masuishi, Toshiki; Bando, Hideaki; Taniguchi, Hiroya; Kadowaki, Shigenori; Ando, Masashi; Ito, Seiji; Tajika, Masahiro; Muro, Kei Share Save Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)Minatogawa, Hiroko; Izawa, Naoki; Shimomura, Kazuhiro; Arioka, Hitoshi; Iihara, Hirotoshi; Sugawara, Mitsuhiro; Morita, Hajime; Mochizuki, Ayako; Nawata, Shuichi; Mishima, Keisuke; Tsuboya, Ayako; Miyaji, Tempei; Honda, Kazunori; Yokomizo, Ayako; Hashimoto, Naoya; Yanagihara, Takeshi; Endo, Junki; Kawaguchi, Takashi; Furuya, Naoki; Sone, Yumiko; Inada, Yusuke; Ohno, Yasushi; Katada, Chikatoshi; Hida, Naoya; Akiyama, Kana; Ichikura, Daisuke; Konomatsu, Akiko; Ogura, Takashi; Yamaguchi, Takuhiro; Nakajima, Takako Eguchi Share Save Nivolumab for cancer of unknown primary (CUP): Initial results from an expanded access program (NivoCUP2, WJOG14620M)Tanizaki, Junko; Yonemori, Kan; Takiguchi, Yuichi; Akiyoshi, Kohei; Komine, Keigo; Onozawa, Yusuke; Sato, Mariko; Hirata, Kenro; Onoe, Takuma; Ohkuma, Ryotaro; Horita, Yosuke; Minami, Hironobu; Honda, Kazunori; Suyama, Koichi; Ito, Akihiko; Chiba, Yasutaka; Nishio, Kazuto; Hayashi, Hidetoshi Share Save Paclitaxel plus cetuximab vs. nivolumab for patients with platinum-refractory recurrent/metastatic head and neck cancerKodama, Hiroyuki; Kadowaki, Shigenori; Wakabayashi, Munehiro; Nakata, Akinobu; Kumanishi, Ryosuke; Nakazawa, Taeko; Ogata, Takatsugu; Matsubara, Yuki; Honda, Kazunori; Masuishi, Toshiki; Narita, Yukiya; Tanigichi, Hiroya; Ando, Masashi; Hanai, Nobuhiro; Muro, Kei Share Save Share Save Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic CancersKodama, Hiroyuki; Masuishi, Toshiki; Wakabayashi, Munehiro; Nakata, Akinobu; Kumanishi, Ryosuke; Nakazawa, Taiko; Ogata, Takatsugu; Matsubara, Yuki; Honda, Kazunori; Narita, Yukiya; Taniguchi, Hiroya; Kadowaki, Shigenori; Ando, Masashi; Muro, Kei Share Save Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplificationSatoh, T.; Barthelemy, P.; Nogova, L.; Honda, K.; Iwasa, S.; Lee, K.; Rha, S.; Ajani, J.; Hangai, N.; Liu, S.; Kremer, J.; Mina, M.; Shitara, K. Share Save Share Save Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma: a retrospective studyKodama, Hiroyuki; Kadowaki, Shigenori; Nakata, Akinobu; Kumanishi, Ryosuke; Nakazawa, Taiko; Ogata, Takatsugu; Matsubara, Yuki; Honda, Kazunori; Masuishi, Toshiki; Narita, Yukiya; Taniguchi, Hiroya; Ando, Masashi; Hanai, Nobuhiro; Muro, Kei Share Save Safety and pharmacokinetics (PK) of tusamitamab ravtansine (tusa) in Japanese patients (pts) with advanced solid tumorsYamazaki, Kentaro; Yoshino, Takayuki; Honda, Kazunori; Kuboki, Yasutoshi; Kawakami, Takeshi; Mitani, Seiichiro; Nakamura, Yoshiaki; Taniguchi, Hiroya; Bando, Hideaki; Tanaka, Tomoyuki; Tada, Keisuke; Fagniez, Nathalie; Muro, Kei Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
